SUNNYVALE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced positive results from a comparative-effectiveness study have been published in JAMA Network Open.
The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a composite of in-hospital stroke, myocardial infarction, or death at 30 days after carotid revascularization, whether TCAR or carotid endarterectomy (CEA).
“Our results demonstrate that VQI centers who offer TCAR achieve lower rates of adverse events after carotid surgery when compared to centers who do not offer the new procedure,” said Jesse Columbo, MD MS, a vascular surgeon at Dartmouth and lead author of the study. “We believe this indicates that centers that offer TCAR are able to better align patients with the best procedure for their individual clinical and anatomic characteristics.”
Read More: https://www.globenewswire.com/news-release/2021/02/25/2182933/0/en/Study-Published-in-JAMA-Finds-Hospital-Availability-of-TCAR-Associated-with-an-Improvement-in-Overall-Outcomes-for-Carotid-Revascularization.html
Study Published in JAMA Finds Hospital Availability of TCAR Associated with an Improvement in Overall Outcomes for Carotid Revascularization
Centers adding transcarotid artery revascularization (TCAR) to their treatment options had improved perioperative outcomes for patients with carotid artery stenosis, according to the Vascular Quality Initiative (VQI) registry.
New technology to combat strokes is being used right here in the Central Valley. One local doctor performed a new type of carotid artery procedure to help his patient reduce the risk of surgical complications.